April 11 (Reuters) - German packaging and medical

equipment maker Gerresheimer is contracted to supply

key players in the market for GLP-1 weight loss drugs, its CEO

Dietmar Siemssen said on Thursday.

"We are serving all key players in the GLP-1 market," he

said during an earnings call. "There are only two key players

there."

The current sales result is thanks to deliveries to these

customers, he added.

GLP-1 is a type of obesity drug such as Novo Nordisk's

Wegovy and Eli Lilly's ( LLY ) Zepbound, which is

administered by injector pens such as those made by

Gerresheimer.